Xanthus’ Symadex Demonstrates Ability To Increase Spinal Cord Remyelination In Multiple Sclerosis Model

Xanthus Pharmaceuticals, Inc. presented preclinical data further supporting the potential for Symadex? to reverse the clinical and pathological signs of multiple sclerosis (MS), including new data demonstrating increased spinal cord remyelination. The study was presented by Dr. Stephen J. Karlik, Ph.D. [click link for full article]

More: continued here

Filed under: Multiple Sclerosis on December 15th, 2007